| Deep‐learning‐based, computer‐aided classifier developed with a small dataset of clinical images surpasses board‐certified dermatologists in skin tumour diagnosis Y Fujisawa, Y Otomo, Y Ogata, Y Nakamura, R Fujita, Y Ishitsuka, ... British Journal of Dermatology 180 (2), 373-381, 2019 | 330 | 2019 |
| Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: a multi‐institutional retrospective study Y Nakamura, R Tanaka, Y Asami, Y Teramoto, T Imamura, S Sato, ... The Journal of dermatology 44 (2), 117-122, 2017 | 207 | 2017 |
| A proposal for a TNM staging system for extramammary Paget disease: retrospective analysis of 301 patients with invasive primary tumors K Ohara, Y Fujisawa, K Yoshino, Y Kiyohara, T Kadono, Y Murata, ... Journal of dermatological science 83 (3), 234-239, 2016 | 138 | 2016 |
| Intratumoral expression levels of PD-L1, GZMA, and HLA-A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma H Inoue, JH Park, K Kiyotani, M Zewde, A Miyashita, M Jinnin, Y Kiniwa, ... Oncoimmunology 5 (9), e1204507, 2016 | 130 | 2016 |
| Chemoradiotherapy with taxane is superior to conventional surgery and radiotherapy in the management of cutaneous angiosarcoma: a multicentre, retrospective study Y Fujisawa, K Yoshino, T Kadono, T Miyagawa, Y Nakamura, M Fujimoto British Journal of Dermatology 171 (6), 1493-1500, 2014 | 125 | 2014 |
| Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma N Yamazaki, Y Kiyohara, H Uhara, H Iizuka, J Uehara, F Otsuka, ... Cancer science 108 (5), 1022-1031, 2017 | 124 | 2017 |
| Serum level of interleukin-6 is increased in nivolumab-associated psoriasiform dermatitis and tumor necrosis factor-α is a biomarker of nivolumab recativity R Tanaka, N Okiyama, M Okune, Y Ishitsuka, R Watanabe, J Furuta, ... Journal of dermatological science 86 (1), 71-73, 2017 | 124 | 2017 |
| Tumor-associated macrophages: therapeutic targets for skin cancer T Fujimura, Y Kambayashi, Y Fujisawa, T Hidaka, S Aiba Frontiers in oncology 8, 3, 2018 | 120 | 2018 |
| Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients K Sakaizawa, A Ashida, A Uchiyama, T Ito, Y Fujisawa, D Ogata, ... Journal of dermatological science 80 (1), 33-37, 2015 | 115 | 2015 |
| Indocyanine green fluorescence‐navigated sentinel node biopsy showed higher sensitivity than the radioisotope or blue dye method, which may help to reduce false‐negative cases … Y Fujisawa, Y Nakamura, Y Kawachi, F Otsuka Journal of surgical oncology 106 (1), 41-45, 2012 | 108 | 2012 |
| Attenuation of UVB-induced sunburn reaction and oxidative DNA damage with no alterations in UVB-induced skin carcinogenesis in Nrf2 gene-deficient mice Y Kawachi, X Xu, S Taguchi, H Sakurai, Y Nakamura, Y Ishii, Y Fujisawa, ... Journal of Investigative Dermatology 128 (7), 1773-1779, 2008 | 102 | 2008 |
| Cutaneous angiosarcoma: the possibility of new treatment options especially for patients with large primary tumor Y Fujisawa, K Yoshino, T Fujimura, Y Nakamura, N Okiyama, Y Ishitsuka, ... Frontiers in oncology 8, 46, 2018 | 101 | 2018 |
| Fluctuations in routine blood count might signal severe immune-related adverse events in melanoma patients treated with nivolumab Y Fujisawa, K Yoshino, A Otsuka, T Funakoshi, T Fujimura, Y Yamamoto, ... Journal of Dermatological Science 88 (2), 225-231, 2017 | 98 | 2017 |
| Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study T Fujimura, Y Sato, K Tanita, Y Kambayashi, A Otsuka, Y Fujisawa, ... Oncotarget 9 (21), 15542, 2018 | 96 | 2018 |
| Clinical and histopathological characteristics and survival analysis of 4594 Japanese patients with melanoma Y Fujisawa, S Yoshikawa, A Minagawa, T Takenouchi, K Yokota, H Uchi, ... Cancer medicine 8 (5), 2146-2156, 2019 | 90 | 2019 |
| Correlation between blood cell count and outcome of melanoma patients treated with anti-PD-1 antibodies Y Nakamura, R Tanaka, H Maruyama, Y Ishitsuka, N Okiyama, ... Japanese journal of clinical oncology 49 (5), 431-437, 2019 | 88 | 2019 |
| Infiltration of PD-1-positive cells in combination with tumor site PD-L1 expression is a positive prognostic factor in cutaneous angiosarcoma Y Honda, A Otsuka, S Ono, Y Yamamoto, JA Seidel, S Morita, M Hirata, ... Oncoimmunology 6 (1), e1253657, 2017 | 78 | 2017 |
| The possibility of deep learning-based, computer-aided skin tumor classifiers Y Fujisawa, S Inoue, Y Nakamura Frontiers in medicine 6, 478177, 2019 | 75 | 2019 |
| The role of sentinel lymph node biopsy in the management of invasive extramammary Paget's disease: Multi-center, retrospective study of 151 patients Y Fujisawa, K Yoshino, Y Kiyohara, T Kadono, Y Murata, H Uhara, ... Journal of Dermatological Science 79 (1), 38-42, 2015 | 75 | 2015 |
| Diagnosis and management of acral lentiginous melanoma Y Nakamura, Y Fujisawa Current treatment options in oncology 19, 1-11, 2018 | 73 | 2018 |
